Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Novartis Ag (NVSEF) R&D In Process (2023 - 2024)

Historic R&D In Process for Novartis Ag (NVSEF) over the last 2 years, with Q4 2024 value amounting to $1.4 billion.

  • Novartis Ag's R&D In Process fell 5141.59% to $1.4 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 billion, marking a year-over-year decrease of 5141.59%. This contributed to the annual value of $1.4 billion for FY2024, which is 5141.59% down from last year.
  • According to the latest figures from Q4 2024, Novartis Ag's R&D In Process is $1.4 billion, which was down 5141.59% from $1.3 billion recorded in Q3 2024.
  • Novartis Ag's R&D In Process' 5-year high stood at $2.9 billion during Q4 2023, with a 5-year trough of $1.3 billion in Q3 2024.